Article info
COVID-19
Effect of IBD medications on COVID-19 outcomes: results from an international registry
- Correspondence to Dr Ryan C Ungaro, The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; ryan.ungaro{at}mssm.edu
Citation
Effect of IBD medications on COVID-19 outcomes: results from an international registry
Publication history
- Received July 15, 2020
- Revised September 28, 2020
- Accepted September 29, 2020
- First published October 20, 2020.
Online issue publication
March 12, 2022
Article Versions
- Previous version (12 March 2022).
- Previous version (12 March 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage